Because the current therapy in polycythemia vera (PV) and essential thrombocythemia (ET)
is aimed at lowering the risk of thrombosis, the risk classification system in these disorders is …

Major causes of morbidity and mortality in polycythemia vera (PV) and essential
thrombocythemia (ET) are represented by thrombosis and bleeding, progression to …

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative
neoplasms characterized by increased rate of cardiovascular events, a varying burden of …

associated with an increased risk of developing arterial and venous thrombotic events which
are a major cause of early morbidity and mortality. 1, 2 These MPNs frequently also evolve …

The clinical course of Polycythemia vera (PV) and Essential Thrombocythemia (ET) is
marked by an high incidence of thrombotic complications, which represent the main cause of …

The optimal management of patients with polycythemia vera (PV) and essential
thrombocythemia (ET) continues to be controversial. Both diseases present diagnostic …

Disease Overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms (MPN) primarily characterized by erythrocytosis and …

Polycythemia vera and essential thrombocythemia (ET) are chronic myeloproliferative
neoplasms associated with thrombotic or hemorrhagic complications, and increased risk of …

The clinical course of polycythemia vera (PV) and essential thrombocythemia (ET) is
characterized by an increased incidence of thrombotic and hemorrhagic complications and …

Polycythemia vera (PV) and essential thrombocythemia (ET) are both classic, relatively
indolent, chronic Philadelphia-chromosome-negative (Ph−) myeloproliferative neoplasms …